ACTIVE Writing Group of the ACTIVE Investigators (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomized controlled trial. Lancet 367:1903–1912Google Scholar

Amerenco, P, Labreuche, J, Lavallee, P et al. (2004). Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 35:2902–2909Google Scholar

Amarenco, P, Bogousslavsky, J, Callahan, A III et al. (2006). High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine 355:549–559Google ScholarPubMed

Amarenco, P, Goldstein, LB, Szarek, M et al. (2007). Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38:3198–3204Google Scholar

Amarenco, P, Labreuche, J (2009). Lipid management in the prevention of stroke: Review and updated meta-analysis of statins for stroke prevention. Lancet Neurology 8:453–463Google Scholar

Amarenco, P, Albers, GW, Denison, H et al. (2017). Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischemic attack of atherosclerotic origin: A subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurology 16:301–310Google Scholar

Antithrombotic Trialists’ (ATT) Collaboration (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. Lancet 373:1849–1860Google Scholar

Apostolakis, S, Sullivan, RM, Olshansky, B et al. (2013). Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT₂R₂ score. Chest 144:1555–1563Google Scholar

Bai, Y, Deng, H, Shantsila, A et al. (2017). Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: Systematic review and meta-analysis. Stroke (epub ahead of print)CrossRefGoogle Scholar

Berger, PB, Bhatt, DL, Fuster, V et al. (2010). Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk actors for vascular disease: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Circulation 121:2575–2583Google Scholar

Bhatt, DL, Flather, MD, Hacke, W et al. (2007). Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiologists 49:1982–1988Google Scholar

Bloomfield, RH, Davenport, J, Babikian, V et al. (2001). Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103:2828–2833Google Scholar

CADISS Trial Investigators (2015). Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): A randomised trial. Lancet Neurology 14:361–367Google Scholar

Canadian Cooperative Study Group (1978). A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New England Journal of Medicine 299:53–59Google Scholar

CAPRIE Steering Committee (1996). A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339Google Scholar

Carnicelli, AP, Caterina, RD, Halperin, JL et al. (2017). Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation (epub ahead of print)Google Scholar

Chan, PH, Chan, EW, Li, WH et al. (2016). Use of the SAMe-TT2R2 Score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence. PLoS One 11:e0150674Google Scholar

Chimowitz, MI, Lynn, MJ, Howlett-Smith, H et al. (2005). Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New England Journal of Medicine 352:1305–1316Google Scholar

Chimowitz, MI, Lynn, MJ, Derdeyn, CP et al. (2011). Stenting versus aggressive medical therapy for intracranial artery stenosis. New England Journal of Medicine 365:993–1003Google Scholar

Collins, R, Armitage, J, Parish, S et al. (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757–767Google ScholarPubMed

Connolly, SJ, Ezekowitz, MD, Yusuf, S et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 361:1139–1151Google Scholar

Connolly, SJ, Eikelboom, J, Joyner, C et al. (2011). Apixaban in patients with atrial fibrillation. New England Journal of Medicine 364:806–817Google Scholar

Connolly, SJ, Milling, TJ Jr, Eikelboom, JW et al. (2016). Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. New England Journal of Medicine 375:1131–1141Google Scholar

Corvol, JC, Bouzamondo, A, Sirol, M et al. (2003). Differential effects of lipid-lowering therapies on stroke prevention: A meta-analysis of randomized trials. Archives of Internal Medicine 163:669–676Google Scholar

Diener, HC, Cunha, L, Forbes, C et al. (1996). European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the Neurological Sciences 143:1–13Google Scholar

Diener, HC, Bogousslavsky, J, Brass, LM et al. (2004). Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised double-blind placebo-controlled trial. Lancet 364:331–337Google Scholar

Diener, HC, Connolly, S, Ezekowitz, MD et al. (2010). Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ishemic attack or stroke: A subgroup analysis of the RE-LY trial. Lancet Neurology 9:1157–1163Google Scholar

Easton, JD, Lopes, RD, Bahit, MC et al. (2012) Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: A subgroup analysis of the ARISTOTLE trial. Lancet Neurology 11:503–511CrossRefGoogle ScholarPubMed

Eikelboom, JW, Connolly, SJ, Brueckmann, M et al. (2013). Dabigatran versus warfarin in patients with mechanical heart valves. New England Journal of Medicine 369:1206–1214Google Scholar

ESPRIT Study Group, Halkes, PH, van Gijn, J et al. (2007). Medium intensity oral anticoagulants versus aspirin after cerebral ischemic of arterial origin (ESPRIT): A randomized controlled trial. Lancet Neurology 6:115–124Google Scholar

Ettehad, D, Emdin, CA, Kiran, A et al. (2016). Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet 387:957–967Google Scholar

Freedman, B, Gersh, BJ, Lip, GY (2015). Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. European Heart Journal 36:653–656Google Scholar

Giugliano, RP, Ruff, CT, Braunwald, E et al. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 369:2093–2104Google Scholar

Giugliano, RP, Sabatine, MS (2015). Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? Journal of the American College of Cardiology 65:2638–2651Google Scholar

Goldstein, LB, Amarenco, P, Szarek, S et al. (2008). Hemorrhagic stroke in Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70:2364–2370Google Scholar

Granger, GB, Alexander, JH, McMurray, JJ et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 365:981–992Google Scholar

Halkes, PH, van Gijn, J for the ESPRIT Study Group (2006). Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 367:1665–1673 [Erratum in Lancet (2007) 369:274]Google Scholar

Hankey, GJ, Patel, MR, Stevens, SR et al. (2012). Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: A subgroup analysis of ROCKET AF. Lancet Neurology 11:315–322Google Scholar

Hart, RG, Pearce, LA, Aguilar, MI (2007). Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine 146:857–867CrossRefGoogle ScholarPubMed

Heidbuchel, H, Verhamme, P, Alings, M et al. (2015). Updated European Heart Rhythm Association Practical Guide on the use of non-vigtmain K antagnoist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467–1507Google Scholar

Kamal, AK, Naqvi, I, Husain, MR et al. (2011). Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database of Systematic Reviews 1:CD008076Google Scholar

Kernan, WN, Ovbiagele, B, Black, HR et al. (2014). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45:2160–2236Google Scholar

Kernan, WN, Viscoli, CM, Furie, KL et al. (2016). Pioglitazone after ischemic stroke or transient ischemic attack. New England Journal of Medicine 374:1321–1331Google Scholar

Kirchhof, P, Benussi, S, Kotecha, D et al. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 37:2893–2962Google Scholar

Johnston, SC, Amarenco, P, Albers, GW et al. (2016). Ticagrelor versus aspirin in acute stroke or transient ischemic attack. New England Journal of Medicine 375:35–43Google Scholar

Lamberts, M, Gislason, GH, Lip, GY et al. (2014). Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: A nationwide cohort study. Circulation 129:1577–1585Google Scholar

Leonardi-Bee, J, Bath, PM, Bousser, MG et al. (2005) Dipyridamole for preventing recurrence ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials. Stroke 36:162–168Google Scholar

Lewington, S, Whitlock, G, Clarke, R et al. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829–1839Google Scholar

Lip, GY, Nieuwlaat, R, Pisters, R et al. (2010a). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 137:263–272CrossRefGoogle ScholarPubMed

Lip, GY, Frison, L, Halperin, JL et al. (2010b). Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drug/Alcohol Concomitantly) score. Journal of American College of Cardiology 57:173–180Google Scholar

Lip, GY, Windecker, S, Huber, K et al. (2014). Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: A joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). European Heart Journal 35:3155–3179Google Scholar

Liu, L, Wang, Z, Gong, L et al. (2009). Blood pressure reduction for the secondary prevention of stroke: A Chinese trial and a systematic review of the literature. Hypertension Research 32:1032–1040Google Scholar

Mant, J, Hobbs, FD, Fletcher, K et al. (2007) Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 370:493–503Google Scholar

Migrino, RQ, Bowers, M, Harmann, L et al. (2011). Carotid plaque regression following 6-month statin therapy assessed by 3 T cardiovascular magnetic resonance: Comparison with ultrasound intima media thickness. Journal of Cardiovascular Magnetic Resonance 13:37Google Scholar

Mohr, JP, Thompson, JL, Lazar, RM et al. (2001). A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New England Journal of Medicine 345:1444–1451Google Scholar

Odden, MC, McClure, LA, Sawaya, BP et al. (2016). Achieved blood pressure and outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension 67:63–69CrossRefGoogle ScholarPubMed

Patel, MR, Mahaffey, KW, Garg, J et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine 365:883–891Google Scholar

Pisters, R, Lane, DA, Nieuwlaat, R et al. (2010). A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 138:1093–1100Google Scholar

Pollack, CV Jr., Reilly, PA, Eikelboom, J et al. (2015). Idarucizumab for dabigatran reversal. New England Journal of Medicine 373:511–520Google Scholar

Powers, WJ, Rabinstein, AA, Ackerson, T et al. (2018). 2018 Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 49:e46–e110Google Scholar

PROGRESS Collaborative Group (2001). Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attacks. Lancet 358:1033–1041Google Scholar

Rash, A, Downes, T, Portner, R et al. (2007). A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 36:151–156Google Scholar

Rost, NS, Giugliano, RP, Ruff, CT et al. (2016). Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: Findings from Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction. Stroke 47:2075–2082Google Scholar

Rothwell, PM, Giles, MF, Chandratheva, A et al. (2007). Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): A prospective population-based sequential comparison. Lancet 370:1432–1442Google Scholar

Rothwell, PM, Howard, SC, Dolan, E et al. (2010). Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375:895–905Google Scholar

Rothwell, PM, Algra, A, Chen, Z et al. (2016). Effects of aspirin on risk and severity of early recurrent stroke after transient ischemic attack and ischemic stroke: Time-course analysis of randomized trials. Lancet 388:365–375CrossRefGoogle Scholar

Ruff, CT, Giugliano, RP, Braunwald, E et al. (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomized trials. Lancet 383:955–962CrossRefGoogle Scholar

Sabatine, MS, Giugliano, RP, Keech, AC et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine 376:1713–1722Google Scholar

Sacco, RL, Diener, HC, Yusuf, S et al. (2008). Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine 359:1238–1251Google Scholar

Seidu, S, Achana, FA, Gray, LJ et al. (2016). Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: A meta-analysis of randomized control trials. Diabetic Medicine 33:280–289Google Scholar

Siontis, KC, Yao, X, Gersh, BJ et al. (2017). Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves. Circulation 135:714–716Google Scholar

Sillesen, H, Amarenco, P, Hennerici, MG et al. (2008). Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: A secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 39:3297–3302Google Scholar

Sivenius, J, Riekkinen, PJ, Smets, P et al. (1991). The European Stroke Prevention Study (ESPS): Results by arterial distribution. Annals of Neurology 29:596–600Google Scholar

SPS3 Investigators (2012). Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New England Journal of Medicine 367:817–825Google Scholar

Stroke Prevention in Atrial Fibrillation Investigators (1991). Stroke prevention in atrial fibrillation study: Final results. Circulation 84:527–539Google Scholar

Stroke Prevention in Reversible Ischemic Trial (SPIRIT) Study Group (1997). A randomized trial of anticoagulants versus aspirin after cerebral ischemic of presumed arterial origin. Annals of Neurology 42:857–865Google Scholar

Sudlow, CL, Mason, G, Maurice, JB et al. (2009). Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database of Systematic Reviews 4:CD001246Google Scholar

Verheugt, FW, Granger, CB (2015). Oral anticoagulants for stroke prevention in atrial fibrillation: Current status, special situations, and unmet needs. Lancet 386:303–310CrossRefGoogle ScholarPubMed

Wang, Y, Wang, Y, Zhao, X et al. (2013). Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine 369:11–19Google Scholar

Webb, AJ, Fischer, U, Mehta, Z et al. (2010). Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: A systematic review and meta-analysis. Lancet 375:906–915Google Scholar

Webb, AJ, Rothwell, PM (2011). Effect of dose and combination of antihypertensives on interindividual blood pressure variability: A systematic review. Stroke 42:2850–2865Google Scholar

Wong, KS, Wang, Y, Leng, X et al. (2013). Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: An updated systematic review and meta-analysis. Circulation 128:1656–1666Google Scholar